Launched CartiZol

Submitted the Common Submission Dossier Template (CSDT) for CartiFill in accordance with the ASEAN Medical Device Directive (AMDD) to the Health Sciences Authority (HSA) in Singapore

Obtained ISO13485:2016 certification

Expanded National Health Insurance coverage for Chondron in collaboration with the Ministry of Health and Welfare (MOHW) and the Health Insurance Review and Assessment Service (HIRA) in Korea

Held the groundbreaking ceremony for the RMS CAMP construction project and announced the global vision, RMS innovation 2028

Initiated Phase III clinical trial of Chondron in Japan following approval of the Investigational New drug (IND) application by the Pharmaceuticals and Medical Devices Agency (PMDA) under the Ministry of Health, Labor and Welfare (MHLW) in Japan

Launched the RMS Innovation Center in Korea

Received the Research Poster Award at the World Congress of Implantology for the preclinical study of TheraForm D conducted jointly by Columbia University and Sewon Cellontech.

Obtained manufacturing approval for RegenPatch from the Ministry of Food and Drug Safety (MFDS) in Korea

Selected as a distinguished contributor to the development of the biopharmaceutical industry in 2016 and awarded the MFDS Award

Registered duck feet-derived BioCollagen in the US FDA DMF

Selected as a member of the presidential economic delegation for the US visit in the healthcare and biotechnology sector, organized by the Korean Chamber of Commerce and Industry

Registered duck foot-derived BioCollagen in the Personal Care Products Council (PCPC) and the International Cosmetic Ingredient Dictionary (ICID)

Registered a domestic patent in Korea for high-concentration BIoCollagen (Invention title: Method for manufacturing High-Concentration Collagen / Patent No. 10-1576060)

Approval of New Health Technology for CartiFill from National Evidence-based healthcare Collaboration Agency (NECA) in Korea

Received the Presidential Commendation at the 42nd Health Day Ceremony hosted by the MOHW in Korea

Registered BioCollagen powder as a DMF with the US FDA

Obtained marketing authorization for the high-concentration BioCollagen filler, LUCIZEN, from the MFDS in Korea

Received the Prime Minister’s Commendation at the 28th Pharmaceutical Day Ceremony hosted by the Korean Pharmaceutical Association

Obtained ISO 22716 certification (Cosmetics-Good Manufacturing Practices) from SGS Korea

Obtained approval for CartiFill from the MFDS

Registered three plant stem cell culture extracts (wild ginseng, Coriander, and sponge gourd) in the International Cosmetic Ingredient Dictionary (ICID) of the Personal Care Products Council (PCPC) in the US

Obtained approval for two medical device products, CartiZol and RegenSeal from MFDS in Korea

Obtained cord blood bank authorization for BabyCell from the MOHW in Korea

Obtained approval for the medical device products OssFill and SurgiFill from the MFDS

Obtained medical device registration and commercialization approval for TheraFll from ANMAT in Argentina

Recognized gel-type Chondron as a New Excellent Technology (NET) by the MOHW in Korea

Obtained approval for TheraForm from MFDS

Obtained CE marking in EU for OssFill (bone graft substitute biomaterial)

Obtained approval of TheraFill from MFDS in Korea

Presented on the topic of “Commercialization Technology for Large-Scale Expansion of Adult Stem Cells” at the ICRS UK Wordshop

Obtained approval for RMS Ossron from MFDS in Korea

Commenced full-scale operations of RMS India and held the official opening ceremony in Lonavalda, India

Obtained CE marking in EU for CartiFill, DuoFill, MRM kit, and SurgiFill

Registered BioCollagen in the US FDA DMF

Registered BioCollagen in the ICID

Conducted a clinical training workshop on Chondron procedures for leading medical staff at the Royal National Orthopedic Hospital in UK

Obtained CE marking in EU for the BioCollagen wound treatment product, TheraForm

Designated as an Advanced Technology Center (ATC) by the MOCIE in Korea

Completed construction of the BioCollagen filler manufacturing facility at the Seongsu-dong in Korea

Obtained ISO13485 certification for RMS regenerative medicine technology

Received the Excellence Award at the 2005 Korea Technology Exhibition for RMS Ossron, presented by the MOCIE in Korea

Received the IR52 Jang Young Sil Award for Chondron, presented by the Ministry of Science and Technology (MOST) in Korea

Obtained the Excellent Korean Technology for Chondron from MOST in Korea

Received the Silver Award at the 2003 Korea Technology Exhibition for Chondron, presented by the MOCIE in Korea

Selected as a Next Generation World-Class Product (Second Half of 2003) for RMS Ossron by the MOCIE in Korea

Listed Chondron for reimbursement under the National Health Insurance system by the HIRA

Launched the family cord blood banking service, BabyCell

Approved Chondron as the 1st biotechnology pharmaceutical product by the MOHW and the MFDS

Obtained KGMP certification from the MFDS

Established the Regenerative Medical System (RMS) business division

Established a cell therapy manufacturing facility (Registration No, 1-4-5593)

Established the Tissue Engineering Research Society